Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Popat R, Augustson B, Gironella M, Lee C, Cannell P, Patel N, Kasinathan RS, Rogers R, Shaikh M, Curry A, Carreño F, Roy-Ghanta S, Opalinska J, Quach H. Popat R, et al. Among authors: augustson b. Blood Cancer J. 2024 Oct 21;14(1):184. doi: 10.1038/s41408-024-01155-y. Blood Cancer J. 2024. PMID: 39433730 Free PMC article.
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Hungria V, et al. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. N Engl J Med. 2024. PMID: 38828933 Clinical Trial.
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Morris K, Pompilus F, Phillips-Jones A, Zhou XL, Fulci G, Sule N, Kremer BE, Opalinska J, Mateos MV, Trudel S; DREAMM-8 Investigators. Dimopoulos MA, et al. N Engl J Med. 2024 Aug 1;391(5):408-421. doi: 10.1056/NEJMoa2403407. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828951 Clinical Trial.
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study.
Ninkovic S, Harrison SJ, Lee JJ, Murphy N, Lee JH, Estell J, Chen VM, Horvath N, Kim K, Eek R, Augustson B, Bang SM, Huang SY, Rajagopal R, Szabo F, Engeler D, Butcher BE, Mollee P, Durie B, Chng WJ, Quach H. Ninkovic S, et al. Among authors: augustson b. Haematologica. 2024 Jul 1;109(7):2229-2238. doi: 10.3324/haematol.2023.284238. Haematologica. 2024. PMID: 38235519 Free PMC article. Clinical Trial.
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Quach H, Benson S, Haysom H, Wilkes AM, Zacher N, Cole-Sinclair M, Miles Prince H, Mollee P, Spencer A, Joy Ho P, Harrison SJ, Lee C, Augustson B, Daly J. Quach H, et al. Among authors: augustson b. Intern Med J. 2018 Feb;48(2):210-220. doi: 10.1111/imj.13707. Intern Med J. 2018. PMID: 29415351 Review.
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Harrison SJ, Quach H, Link E, Feng H, Dean J, Copeman M, Van De Velde H, Schwarer A, Baker B, Spencer A, Catalano J, Campbell P, Augustson B, Romeril K, Prince HM. Harrison SJ, et al. Among authors: augustson b. Am J Hematol. 2015 May;90(5):E86-91. doi: 10.1002/ajh.23967. Epub 2015 Feb 27. Am J Hematol. 2015. PMID: 25651830 Free article. Clinical Trial.
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia.
Creeper K, Augustson B, Kusel K, Fulham MJ, Ho J, Quach H, Mollee P, Weber N, Talaulikar D, Johnston A, Murphy N, Joshua D, Ward C, Ling S, Gibson J, Szer J, Harrison S, Zannettino A, Jaksic W, Lee C, Spencer A, Kalff A, Szabo F, Romeril K, Chan H, Gibbs S, Horvath N, Prince HM. Creeper K, et al. Among authors: augustson b. Intern Med J. 2021 Oct;51(10):1707-1712. doi: 10.1111/imj.15457. Intern Med J. 2021. PMID: 34664367
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM. Talaulikar D, et al. Among authors: augustson b. Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311. Intern Med J. 2017. PMID: 28076910
Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
Lee OL, Horvath N, Lee C, Joshua D, Ho J, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Talaulikar D, Brown R, Augustson B, Ling S, Jaksic W, Gibson J, Kalff A, Johnston A, Kalro A, Ward C, Prince HM, Zannettino A. Lee OL, et al. Among authors: augustson b. Intern Med J. 2017 Aug;47(8):938-951. doi: 10.1111/imj.13502. Intern Med J. 2017. PMID: 28782211
63 results